Trial Outcomes & Findings for Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors (NCT NCT04972110)
NCT ID: NCT04972110
Last Updated: 2025-10-30
Results Overview
Treatment Related Treatment-Emergent Adverse Events (TRAE) with ≥3 CTCAE Grade
Recruitment status
TERMINATED
Study phase
PHASE1/PHASE2
Target enrollment
156 participants
Primary outcome timeframe
Start of treatment to 30 days post last dose, up to 23.7 months
Results posted on
2025-10-30
Participant Flow
Participant milestones
| Measure |
Arm 1: 50mg QD camonsertib + 100mg QD niraparib, 3d on/4d off, weekly
50 mg RP-3500 (camonsertib) taken QD (once a day) orally in combination with 100 mg niraparib taken QD orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 1: 80mg QD camonsertib + 100mg QD niraparib, 2d on/5d off, weekly
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 2 days on and 5 days off schedule for 3 weeks (21 day cycle)
|
Arm 1: 80mg QD camonsertib + 100mg QD niraparib, 3d on/4d off, weekly
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 1: 80mg QD camonsertib + 100mg QD niraparib, 2d on/5d off, 2 weeks on/1 week off
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 2 days on and 5 days off schedule for 2 weeks on and 1 week off (21 day cycle)
|
Arm 1: 70mg QD camonsertib + 100mg QD niraparib, 3d on/4d off, weekly
70 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 2 days on and 5 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 150mg BID olaparib, 3d on/4d off, weekly
50 mg RP-3500 (camonsertib) taken QD orally in combination with 150 mg olaparib taken BID (twice a day) orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 100mg BID olaparib, 3d on/4d off, weekly
50 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg olaparib taken BID orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 200 mg QD olaparib, 3d on/4 d off, weekly
50 mg RP-3500 (camonsertib) taken QD orally in combination with 200 mg olaparib taken QD orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 80mg QD camonsertib + 150mg BID olaparib, 3d on/4d off, weekly
80 mg RP-3500 (camonsertib) taken QD orally in combination with 150 mg olaparib taken BID orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 100mg BID olaparib, 2d on/5d off, weekly
50 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg olaparib taken BID orally, same day on a 2 days on and 5 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 80mg QD camonsertib + 100mg BID olaparib, 2d on/5d off, 2w on/1w off
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg olaparib taken BID orally, same day on a 2 days on and 5 days off schedule for 2 weeks on and 1 week off (21 day cycle)
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
9
|
24
|
3
|
23
|
8
|
7
|
19
|
5
|
3
|
26
|
29
|
|
Overall Study
COMPLETED
|
1
|
4
|
1
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
8
|
20
|
2
|
23
|
8
|
7
|
18
|
4
|
2
|
26
|
29
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors
Baseline characteristics by cohort
| Measure |
Arm 1: 50mg QD camonsertib + 100mg QD niraparib, 3d on/4d off, weekly
n=9 Participants
50 mg RP-3500 (camonsertib) taken QD (once a day) orally in combination with 100 mg niraparib taken QD orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 1: 80mg QD camonsertib + 100mg QD niraparib, 2d on/5d off, weekly
n=24 Participants
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 2 days on and 5 days off schedule for 3 weeks (21 day cycle)
|
Arm 1: 80mg QD camonsertib + 100mg QD niraparib, 3d on/4d off, weekly
n=3 Participants
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 1: 80mg QD camonsertib + 100mg QD niraparib, 2d on/5d off, 2 weeks on/1 week off
n=23 Participants
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 2 days on and 5 days off schedule for 2 weeks on and 1 week off (21 day cycle)
|
Arm 1: 70mg QD camonsertib + 100mg QD niraparib, 3d on/4d off, weekly
n=8 Participants
70 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 2 days on and 5 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 150mg BID olaparib, 3d on/4d off, weekly
n=7 Participants
50 mg RP-3500 (camonsertib) taken QD orally in combination with 150 mg olaparib taken BID (twice a day) orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 100mg BID olaparib, 3d on/4d off, weekly
n=19 Participants
50 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg olaparib taken BID orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 200 mg QD olaparib, 3d on/4 d off, weekly
n=5 Participants
50 mg RP-3500 (camonsertib) taken QD orally in combination with 200 mg olaparib taken QD orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 80mg QD camonsertib + 150mg BID olaparib, 3d on/4d off, weekly
n=3 Participants
80 mg RP-3500 (camonsertib) taken QD orally in combination with 150 mg olaparib taken BID orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 100mg BID olaparib, 2d on/5d off, weekly
n=26 Participants
50 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg olaparib taken BID orally, same day on a 2 days on and 5 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 80mg QD camonsertib + 100mg BID olaparib, 2d on/5d off, 2w on/1w off
n=29 Participants
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg olaparib taken BID orally, same day on a 2 days on and 5 days off schedule for 2 weeks on and 1 week off (21 day cycle)
|
Total
n=156 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Customized
Age
|
60.9 years
STANDARD_DEVIATION 13.51 • n=5 Participants
|
61.7 years
STANDARD_DEVIATION 7.70 • n=7 Participants
|
61.7 years
STANDARD_DEVIATION 15.18 • n=5 Participants
|
56.4 years
STANDARD_DEVIATION 9.01 • n=4 Participants
|
63.1 years
STANDARD_DEVIATION 12.14 • n=21 Participants
|
53.1 years
STANDARD_DEVIATION 14.24 • n=8 Participants
|
56.8 years
STANDARD_DEVIATION 14.60 • n=8 Participants
|
59.8 years
STANDARD_DEVIATION 12.40 • n=24 Participants
|
59.3 years
STANDARD_DEVIATION 21.08 • n=42 Participants
|
58.8 years
STANDARD_DEVIATION 13.38 • n=42 Participants
|
59.2 years
STANDARD_DEVIATION 13.73 • n=42 Participants
|
58.9 years
STANDARD_DEVIATION 12.25 • n=42 Participants
|
|
Sex: Female, Male
Female
|
6 Participants
n=5 Participants
|
20 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
19 Participants
n=4 Participants
|
8 Participants
n=21 Participants
|
3 Participants
n=8 Participants
|
12 Participants
n=8 Participants
|
2 Participants
n=24 Participants
|
1 Participants
n=42 Participants
|
15 Participants
n=42 Participants
|
16 Participants
n=42 Participants
|
104 Participants
n=42 Participants
|
|
Sex: Female, Male
Male
|
3 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
4 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
4 Participants
n=8 Participants
|
7 Participants
n=8 Participants
|
3 Participants
n=24 Participants
|
2 Participants
n=42 Participants
|
11 Participants
n=42 Participants
|
13 Participants
n=42 Participants
|
52 Participants
n=42 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
4 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
2 Participants
n=42 Participants
|
3 Participants
n=42 Participants
|
11 Participants
n=42 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
9 Participants
n=5 Participants
|
22 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
18 Participants
n=4 Participants
|
8 Participants
n=21 Participants
|
6 Participants
n=8 Participants
|
18 Participants
n=8 Participants
|
5 Participants
n=24 Participants
|
3 Participants
n=42 Participants
|
23 Participants
n=42 Participants
|
26 Participants
n=42 Participants
|
141 Participants
n=42 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
4 Participants
n=42 Participants
|
PRIMARY outcome
Timeframe: Start of treatment to 30 days post last dose, up to 23.7 monthsTreatment Related Treatment-Emergent Adverse Events (TRAE) with ≥3 CTCAE Grade
Outcome measures
| Measure |
Arm 1: 50mg QD camonsertib + 100mg QD niraparib, 3d on/4d off, weekly
n=9 Participants
50 mg RP-3500 (camonsertib) taken QD (once a day) orally in combination with 100 mg niraparib taken QD orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 1: 80mg QD camonsertib + 100mg QD niraparib, 2d on/5d off, weekly
n=24 Participants
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 2 days on and 5 days off schedule for 3 weeks (21 day cycle)
|
Arm 1: 80mg QD camonsertib + 100mg QD niraparib, 3d on/4d off, weekly
n=3 Participants
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 1: 80mg QD camonsertib + 100mg QD niraparib, 2d on/5d off, 2 weeks on/1 week off
n=23 Participants
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 2 days on and 5 days off schedule for 2 weeks on and 1 week off (21 day cycle)
|
Arm 1: 70mg QD camonsertib + 100mg QD niraparib, 3d on/4d off, weekly
n=8 Participants
70 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 2 days on and 5 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 150mg BID olaparib, 3d on/4d off, weekly
n=7 Participants
50 mg RP-3500 (camonsertib) taken QD orally in combination with 150 mg olaparib taken BID (twice a day) orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 100mg BID olaparib, 3d on/4d off, weekly
n=19 Participants
50 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg olaparib taken BID orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 200 mg QD olaparib, 3d on/4 d off, weekly
n=5 Participants
50 mg RP-3500 (camonsertib) taken QD orally in combination with 200 mg olaparib taken QD orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 80mg QD camonsertib + 150mg BID olaparib, 3d on/4d off, weekly
n=3 Participants
80 mg RP-3500 (camonsertib) taken QD orally in combination with 150 mg olaparib taken BID orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 100mg BID olaparib, 2d on/5d off, weekly
n=26 Participants
50 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg olaparib taken BID orally, same day on a 2 days on and 5 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 80mg QD camonsertib + 100mg BID olaparib, 2d on/5d off, 2w on/1w off
n=29 Participants
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg olaparib taken BID orally, same day on a 2 days on and 5 days off schedule for 2 weeks on and 1 week off (21 day cycle)
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Determine the Safety and Tolerability of Niraparib or Olaparib in Combination With RP-3500 in Patients With Molecularly Selected Solid Tumors
|
8 Participants
|
20 Participants
|
3 Participants
|
12 Participants
|
7 Participants
|
6 Participants
|
16 Participants
|
5 Participants
|
3 Participants
|
16 Participants
|
23 Participants
|
PRIMARY outcome
Timeframe: During 21 days (one cycle) from the initiation of the study treatmentFrequency of DLTs during the DLT observation period
Outcome measures
| Measure |
Arm 1: 50mg QD camonsertib + 100mg QD niraparib, 3d on/4d off, weekly
n=8 Participants
50 mg RP-3500 (camonsertib) taken QD (once a day) orally in combination with 100 mg niraparib taken QD orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 1: 80mg QD camonsertib + 100mg QD niraparib, 2d on/5d off, weekly
n=22 Participants
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 2 days on and 5 days off schedule for 3 weeks (21 day cycle)
|
Arm 1: 80mg QD camonsertib + 100mg QD niraparib, 3d on/4d off, weekly
n=3 Participants
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 1: 80mg QD camonsertib + 100mg QD niraparib, 2d on/5d off, 2 weeks on/1 week off
n=22 Participants
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 2 days on and 5 days off schedule for 2 weeks on and 1 week off (21 day cycle)
|
Arm 1: 70mg QD camonsertib + 100mg QD niraparib, 3d on/4d off, weekly
n=8 Participants
70 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 2 days on and 5 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 150mg BID olaparib, 3d on/4d off, weekly
n=6 Participants
50 mg RP-3500 (camonsertib) taken QD orally in combination with 150 mg olaparib taken BID (twice a day) orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 100mg BID olaparib, 3d on/4d off, weekly
n=17 Participants
50 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg olaparib taken BID orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 200 mg QD olaparib, 3d on/4 d off, weekly
n=4 Participants
50 mg RP-3500 (camonsertib) taken QD orally in combination with 200 mg olaparib taken QD orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 80mg QD camonsertib + 150mg BID olaparib, 3d on/4d off, weekly
n=3 Participants
80 mg RP-3500 (camonsertib) taken QD orally in combination with 150 mg olaparib taken BID orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 100mg BID olaparib, 2d on/5d off, weekly
n=26 Participants
50 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg olaparib taken BID orally, same day on a 2 days on and 5 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 80mg QD camonsertib + 100mg BID olaparib, 2d on/5d off, 2w on/1w off
n=27 Participants
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg olaparib taken BID orally, same day on a 2 days on and 5 days off schedule for 2 weeks on and 1 week off (21 day cycle)
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Define the Recommended Phase 2 Dose (RP2D) of RP-3500 in Combination With Niraparib or Olaparib in Patients With Molecularly Selected Solid Tumors
|
1 Participants
|
1 Participants
|
3 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
6 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
3 Participants
|
Adverse Events
Arm 1: 50mg QD camonsertib + 100mg QD niraparib, 3d on/4d off, weekly
Serious events: 4 serious events
Other events: 9 other events
Deaths: 3 deaths
Arm 1: 80mg QD camonsertib + 100mg QD niraparib, 2d on/5d off, weekly
Serious events: 8 serious events
Other events: 24 other events
Deaths: 10 deaths
Arm 1: 80mg QD camonsertib + 100mg QD niraparib, 3d on/4d off, weekly
Serious events: 2 serious events
Other events: 3 other events
Deaths: 0 deaths
Arm 1: 80mg QD camonsertib + 100mg QD niraparib, 2d on/5d off, 2 weeks on/1 week off
Serious events: 7 serious events
Other events: 23 other events
Deaths: 8 deaths
Arm 1: 70mg QD camonsertib + 100mg QD niraparib, 2d on/5d off, weekly
Serious events: 3 serious events
Other events: 8 other events
Deaths: 1 deaths
Arm 2: 50mg QD camonsertib + 150mg BID olaparib, 3d on/4d off, weekly
Serious events: 1 serious events
Other events: 7 other events
Deaths: 4 deaths
Arm 2: 50mg QD camonsertib + 100mg BID olaparib, 3d on/4d off, weekly
Serious events: 11 serious events
Other events: 19 other events
Deaths: 10 deaths
Arm 2: 50mg QD camonsertib + 200 mg QD olaparib, 3d on/4 d off, weekly
Serious events: 2 serious events
Other events: 5 other events
Deaths: 1 deaths
Arm 2: 80mg QD camonsertib + 150mg BID olaparib, 3d on/4d off, weekly
Serious events: 1 serious events
Other events: 3 other events
Deaths: 1 deaths
Arm 2: 50mg QD camonsertib + 100mg BID olaparib, 2d on/5d off, weekly
Serious events: 8 serious events
Other events: 26 other events
Deaths: 6 deaths
Arm 2: 80mg QD camonsertib + 100mg BID olaparib, 2d on/5d off, 2w on/1w off
Serious events: 8 serious events
Other events: 27 other events
Deaths: 5 deaths
Serious adverse events
| Measure |
Arm 1: 50mg QD camonsertib + 100mg QD niraparib, 3d on/4d off, weekly
n=9 participants at risk
50 mg RP-3500 (camonsertib) taken QD (once a day) orally in combination with 100 mg niraparib taken QD orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 1: 80mg QD camonsertib + 100mg QD niraparib, 2d on/5d off, weekly
n=24 participants at risk
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 2 days on and 5 days off schedule for 3 weeks (21 day cycle)
|
Arm 1: 80mg QD camonsertib + 100mg QD niraparib, 3d on/4d off, weekly
n=3 participants at risk
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 1: 80mg QD camonsertib + 100mg QD niraparib, 2d on/5d off, 2 weeks on/1 week off
n=23 participants at risk
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 2 days on and 5 days off schedule for 2 weeks on and 1 week off (21 day cycle)
|
Arm 1: 70mg QD camonsertib + 100mg QD niraparib, 2d on/5d off, weekly
n=8 participants at risk
70 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 2 days on and 5 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 150mg BID olaparib, 3d on/4d off, weekly
n=7 participants at risk
50 mg RP-3500 (camonsertib) taken QD orally in combination with 150 mg olaparib taken BID (twice a day) orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 100mg BID olaparib, 3d on/4d off, weekly
n=19 participants at risk
50 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg olaparib taken BID orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 200 mg QD olaparib, 3d on/4 d off, weekly
n=5 participants at risk
50 mg RP-3500 (camonsertib) taken QD orally in combination with 200 mg olaparib taken QD orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 80mg QD camonsertib + 150mg BID olaparib, 3d on/4d off, weekly
n=3 participants at risk
80 mg RP-3500 (camonsertib) taken QD orally in combination with 150 mg olaparib taken BID orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 100mg BID olaparib, 2d on/5d off, weekly
n=26 participants at risk
50 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg olaparib taken BID orally, same day on a 2 days on and 5 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 80mg QD camonsertib + 100mg BID olaparib, 2d on/5d off, 2w on/1w off
n=29 participants at risk
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg olaparib taken BID orally, same day on a 2 days on and 5 days off schedule for 2 weeks on and 1 week off (21 day cycle)
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Nervous system disorders
Hemiparesis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.5%
2/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.5%
2/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Blood and lymphatic system disorders
Neutrophil count decreased/ Neutropenia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Blood and lymphatic system disorders
Platelet count decreased/ Thrombocytopenia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Cardiac disorders
Acute coronary syndrome
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Endocrine disorders
Adrenal insufficiency
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
13.0%
3/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Large intestinal obstruction
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Nausea
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Obstruction gastric
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Vomiting
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
General disorders and administration site conditions
Non-cardiac chest pain
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
General disorders and administration site conditions
Pyrexia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Hepatobiliary disorders
Biliary obstruction
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Hepatobiliary disorders
Hepatic failure
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Bacteraemia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
COVID-19
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Device related infection
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Pneumonia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Pneumonia fungal
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Sepsis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Skin infection
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.7%
2/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
7.7%
2/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Wound infection
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Rib fracture
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Thermal burn
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Vascular pseudoaneurysm
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute myeloid leukaemia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer pain
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemia
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to meninges
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour haemorrhage
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour pain
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Nervous system disorders
Spinal cord compression
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
7.7%
2/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Vascular disorders
Embolism
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
Other adverse events
| Measure |
Arm 1: 50mg QD camonsertib + 100mg QD niraparib, 3d on/4d off, weekly
n=9 participants at risk
50 mg RP-3500 (camonsertib) taken QD (once a day) orally in combination with 100 mg niraparib taken QD orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 1: 80mg QD camonsertib + 100mg QD niraparib, 2d on/5d off, weekly
n=24 participants at risk
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 2 days on and 5 days off schedule for 3 weeks (21 day cycle)
|
Arm 1: 80mg QD camonsertib + 100mg QD niraparib, 3d on/4d off, weekly
n=3 participants at risk
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 1: 80mg QD camonsertib + 100mg QD niraparib, 2d on/5d off, 2 weeks on/1 week off
n=23 participants at risk
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 2 days on and 5 days off schedule for 2 weeks on and 1 week off (21 day cycle)
|
Arm 1: 70mg QD camonsertib + 100mg QD niraparib, 2d on/5d off, weekly
n=8 participants at risk
70 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg niraparib taken QD orally, same day on a 2 days on and 5 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 150mg BID olaparib, 3d on/4d off, weekly
n=7 participants at risk
50 mg RP-3500 (camonsertib) taken QD orally in combination with 150 mg olaparib taken BID (twice a day) orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 100mg BID olaparib, 3d on/4d off, weekly
n=19 participants at risk
50 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg olaparib taken BID orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 200 mg QD olaparib, 3d on/4 d off, weekly
n=5 participants at risk
50 mg RP-3500 (camonsertib) taken QD orally in combination with 200 mg olaparib taken QD orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 80mg QD camonsertib + 150mg BID olaparib, 3d on/4d off, weekly
n=3 participants at risk
80 mg RP-3500 (camonsertib) taken QD orally in combination with 150 mg olaparib taken BID orally, same day on a 3 days on and 4 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 50mg QD camonsertib + 100mg BID olaparib, 2d on/5d off, weekly
n=26 participants at risk
50 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg olaparib taken BID orally, same day on a 2 days on and 5 days off schedule for 3 weeks (21 day cycle)
|
Arm 2: 80mg QD camonsertib + 100mg BID olaparib, 2d on/5d off, 2w on/1w off
n=29 participants at risk
80 mg RP-3500 (camonsertib) taken QD orally in combination with 100 mg olaparib taken BID orally, same day on a 2 days on and 5 days off schedule for 2 weeks on and 1 week off (21 day cycle)
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
General disorders and administration site conditions
Crying
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Urostomy complication
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Rotator cuff syndrome
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Sacral pain
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Blood and lymphatic system disorders
Anaemia
|
88.9%
8/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
83.3%
20/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
100.0%
3/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
65.2%
15/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
75.0%
6/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
85.7%
6/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
89.5%
17/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
80.0%
4/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
100.0%
3/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
92.3%
24/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
65.5%
19/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Blood and lymphatic system disorders
Lymphopenia
|
22.2%
2/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
16.7%
4/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.7%
2/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
28.6%
2/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
40.0%
2/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
7.7%
2/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
13.8%
4/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Blood and lymphatic system disorders
Neutrophil count decreased/ Neutropenia
|
44.4%
4/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
62.5%
15/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
100.0%
3/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
21.7%
5/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
28.6%
2/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
73.7%
14/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
60.0%
3/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
100.0%
3/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
50.0%
13/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
72.4%
21/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Blood and lymphatic system disorders
Platelet count decreased/ Thrombocytopenia
|
33.3%
3/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
41.7%
10/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
100.0%
3/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
13.0%
3/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
57.1%
4/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
36.8%
7/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
40.0%
2/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
19.2%
5/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
37.9%
11/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Blood and lymphatic system disorders
WBC count decreased/ Leukopenia
|
33.3%
3/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
8/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
52.6%
10/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
60.0%
3/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
30.8%
8/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
34.5%
10/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Cardiac disorders
Cardiac discomfort
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Cardiac disorders
Cardiac failure
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Cardiac disorders
Cardiomyopathy
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Cardiac disorders
Palpitations
|
22.2%
2/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.3%
2/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.7%
2/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Cardiac disorders
Sinus bradycardia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Cardiac disorders
Sinus tachycardia
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
16.7%
4/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
6.9%
2/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Ear and labyrinth disorders
Ear pain
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Ear and labyrinth disorders
Hypoacusis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Ear and labyrinth disorders
Tinnitus
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
6.9%
2/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
6.9%
2/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Endocrine disorders
Adrenal insufficiency
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Eye disorders
Dry eye
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Eye disorders
Eye pain
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Eye disorders
Eye swelling
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Eye disorders
Lacrimation increased
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Eye disorders
Photophobia
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Eye disorders
Vision blurred
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.7%
2/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Eye disorders
Visual impairment
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Eye disorders
Vitreous floaters
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Abdominal distension
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
3/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
13.0%
3/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.5%
2/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
40.0%
2/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
6.9%
2/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Abdominal pain
|
22.2%
2/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
16.7%
4/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
30.4%
7/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
25.0%
2/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
6.9%
2/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Abdominal pain lower
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
25.0%
2/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Anal incontinence
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.3%
2/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Change of bowel habit
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Constipation
|
22.2%
2/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
41.7%
10/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
21.7%
5/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.5%
2/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
19.2%
5/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.7%
6/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Crohn's disease
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Dental caries
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Diarrhoea
|
33.3%
3/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
29.2%
7/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
21.7%
5/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
25.0%
2/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
28.6%
2/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
15.8%
3/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
23.1%
6/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
17.2%
5/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
3/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
25.0%
2/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Duodenitis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.3%
2/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
7.7%
2/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Dysphagia
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Flatulence
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.5%
2/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Gastrointestinal disorder
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Gastrointestinal wall thickening
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.7%
2/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
7.7%
2/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Gingival bleeding
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Haematochezia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Hiatus hernia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Large intestinal haemorrhage
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Large intestinal obstruction
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Large intestinal ulcer
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Nausea
|
55.6%
5/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
37.5%
9/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
47.8%
11/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
62.5%
5/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
26.3%
5/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
40.0%
2/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
66.7%
2/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
26.9%
7/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
41.4%
12/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Obstruction gastric
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Oesophagitis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Oral pain
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Proctalgia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Rectal ulcer
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Retching
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Stomatitis
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.3%
2/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
13.0%
3/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
15.8%
3/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Toothache
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Varices oesophageal
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Gastrointestinal disorders
Vomiting
|
22.2%
2/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
8/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
47.8%
11/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
25.0%
2/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
28.6%
2/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.5%
2/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
40.0%
2/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
15.4%
4/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
17.2%
5/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
General disorders and administration site conditions
Asthenia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
General disorders and administration site conditions
Axillary pain
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
General disorders and administration site conditions
Chest discomfort
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
General disorders and administration site conditions
Chills
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
General disorders and administration site conditions
Deformity
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
General disorders and administration site conditions
Early satiety
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
General disorders and administration site conditions
Face oedema
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
General disorders and administration site conditions
Fatigue
|
44.4%
4/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
70.8%
17/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
66.7%
2/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
39.1%
9/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
37.5%
3/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
28.6%
2/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
36.8%
7/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
60.0%
3/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
66.7%
2/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
34.6%
9/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
34.5%
10/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
General disorders and administration site conditions
Influenza like illness
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.3%
2/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
General disorders and administration site conditions
Localised oedema
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
General disorders and administration site conditions
Malaise
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.5%
2/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
6.9%
2/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
General disorders and administration site conditions
Mucosal inflammation
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
General disorders and administration site conditions
Non-cardiac chest pain
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.7%
2/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
General disorders and administration site conditions
Oedema peripheral
|
22.2%
2/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
3/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
15.8%
3/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
13.8%
4/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
General disorders and administration site conditions
Pain
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
25.0%
2/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
General disorders and administration site conditions
Peripheral swelling
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
General disorders and administration site conditions
Pyrexia
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
66.7%
2/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.7%
2/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
7.7%
2/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
General disorders and administration site conditions
Suprapubic pain
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
General disorders and administration site conditions
Swelling face
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
General disorders and administration site conditions
Temperature intolerance
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Immune system disorders
Hypersensitivity
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Acute sinusitis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Bronchitis
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
COVID-19
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.8%
5/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.5%
2/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Cellulitis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Chronic sinusitis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Conjunctivitis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Cystitis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Device related infection
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Folliculitis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Gingivitis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Lower respiratory tract infection
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Ludwig angina
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Osteomyelitis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Periorbital cellulitis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Pneumonia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.5%
2/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Pneumonia fungal
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Pseudomonas infection
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Rash pustular
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Sinusitis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Skin infection
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Streptococcal infection
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Tooth abscess
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Tooth infection
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
3/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.5%
2/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.3%
3/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Urinary tract infection
|
22.2%
2/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
3/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.7%
2/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
7.7%
2/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Vaginal infection
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Infections and infestations
Wound infection
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Fall
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
3/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.5%
2/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
7.7%
2/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Foot fracture
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Fractured sacrum
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Head injury
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Incision site inflammation
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Lower limb fracture
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Meniscus injury
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Muscle strain
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Pelvic fracture
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.3%
2/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Post procedural bile leak
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Rib fracture
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Skin abrasion
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Skin wound
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Soft tissue injury
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Spinal compression fracture
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Spinal fracture
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Injury, poisoning and procedural complications
Vascular access complication
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.3%
2/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
28.6%
2/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.5%
2/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
40.0%
2/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
11.5%
3/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
6.9%
2/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.3%
2/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
60.0%
3/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
15.4%
4/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
13.8%
4/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Investigations
Blood albumin increased
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Investigations
Blood alkaline phosphatase increased
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.3%
2/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.5%
2/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
60.0%
3/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
11.5%
3/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.3%
3/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Investigations
Blood bicarbonate decreased
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
40.0%
2/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Investigations
Blood chloride decreased
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Investigations
Blood creatinine increased
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
28.6%
2/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.3%
3/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Investigations
Blood lactate dehydrogenase increased
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.3%
2/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Investigations
Blood pressure diastolic increased
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Investigations
Blood urea increased
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Investigations
Gamma-glutamyltransferase increased
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Investigations
Heart rate increased
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Investigations
Neutrophil count increased
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Investigations
Nitrite urine present
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Investigations
Protein total decreased
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Investigations
Thyroxine increased
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Investigations
Urine analysis abnormal
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
7.7%
2/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Investigations
Weight decreased
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.3%
2/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Investigations
Weight increased
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Investigations
White blood cells urine positive
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Metabolism and nutrition disorders
Decreased appetite
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.8%
5/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
66.7%
2/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.7%
2/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
25.0%
2/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
21.1%
4/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
60.0%
3/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
15.4%
4/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
13.8%
4/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Metabolism and nutrition disorders
Dehydration
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
16.7%
4/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.7%
2/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
15.8%
3/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Metabolism and nutrition disorders
Hypermagnesaemia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
7.7%
2/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
6.9%
2/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Metabolism and nutrition disorders
Hypernatraemia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Metabolism and nutrition disorders
Hyperphosphataemia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
22.2%
2/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
40.0%
2/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
6.9%
2/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
22.2%
2/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
22.2%
2/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
3/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.7%
2/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
40.0%
2/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
6.9%
2/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Metabolism and nutrition disorders
Hypophagia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Metabolism and nutrition disorders
Hypouricaemia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Metabolism and nutrition disorders
Increased appetite
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Metabolism and nutrition disorders
Vitamin D deficiency
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.3%
2/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
15.8%
3/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
15.4%
4/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
13.8%
4/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
29.2%
7/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
13.0%
3/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
15.4%
4/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
17.2%
5/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Groin pain
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc degeneration
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Joint stiffness
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
3/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
25.0%
2/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.5%
2/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
66.7%
2/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Muscle tightness
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.3%
2/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
17.4%
4/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.5%
2/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
6.9%
2/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.5%
2/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
7.7%
2/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal discomfort
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.7%
2/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
7.7%
2/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.3%
3/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Osteonecrosis of jaw
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
23.1%
6/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.3%
3/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Pain in jaw
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Plantar fasciitis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Musculoskeletal and connective tissue disorders
Soft tissue mass
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer pain
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to central nervous system
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour pain
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.5%
2/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Nervous system disorders
Aphasia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Nervous system disorders
Aura
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Nervous system disorders
Brain fog
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Nervous system disorders
Dizziness
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
17.4%
4/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
25.0%
2/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
15.8%
3/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
7.7%
2/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
13.8%
4/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Nervous system disorders
Dysarthria
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Nervous system disorders
Dysgeusia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.7%
2/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
25.0%
2/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Nervous system disorders
Dyskinesia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Nervous system disorders
Encephalopathy
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Nervous system disorders
Extrapyramidal disorder
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Nervous system disorders
Headache
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
29.2%
7/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
26.1%
6/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
28.6%
2/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
15.8%
3/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
15.4%
4/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
13.8%
4/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Nervous system disorders
Lethargy
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Nervous system disorders
Migraine
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Nervous system disorders
Presyncope
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Nervous system disorders
Seizure
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Nervous system disorders
Syncope
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.5%
2/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Nervous system disorders
Taste disorder
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Nervous system disorders
Toxic encephalopathy
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Nervous system disorders
Vocal cord paralysis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Psychiatric disorders
Agitation
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
3/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
10.3%
3/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Psychiatric disorders
Delirium
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Psychiatric disorders
Depression
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.3%
2/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Psychiatric disorders
Emotional distress
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Psychiatric disorders
Insomnia
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.8%
5/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
17.4%
4/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
7.7%
2/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
13.8%
4/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Psychiatric disorders
Mood swings
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Renal and urinary disorders
Chronic kidney disease
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Renal and urinary disorders
Dysuria
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.3%
2/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.7%
2/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Renal and urinary disorders
Hydronephrosis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Renal and urinary disorders
Micturition urgency
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Renal and urinary disorders
Pollakiuria
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
6.9%
2/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Renal and urinary disorders
Proteinuria
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Renal and urinary disorders
Urge incontinence
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Renal and urinary disorders
Urinary incontinence
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Renal and urinary disorders
Urinary tract pain
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Renal and urinary disorders
Urine flow decreased
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Reproductive system and breast disorders
Breast disorder
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Reproductive system and breast disorders
Breast pain
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Reproductive system and breast disorders
Erectile dysfunction
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Reproductive system and breast disorders
Pelvic pain
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Reproductive system and breast disorders
Penile discomfort
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Reproductive system and breast disorders
Vaginal discharge
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Reproductive system and breast disorders
Vaginal haemorrhage
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
33.3%
3/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.3%
2/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.7%
2/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
21.1%
4/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
66.7%
2/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
6.9%
2/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Respiratory, thoracic and mediastinal disorders
Dry throat
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
44.4%
4/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.8%
5/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
66.7%
2/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
13.0%
3/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
37.5%
3/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
28.6%
2/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
15.8%
3/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
66.7%
2/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
11.5%
3/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
15.8%
3/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Respiratory, thoracic and mediastinal disorders
Laryngospasm
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Respiratory, thoracic and mediastinal disorders
Lung infiltration
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.3%
2/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
6.9%
2/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
6.9%
2/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Respiratory, thoracic and mediastinal disorders
Rhinitis allergic
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Respiratory, thoracic and mediastinal disorders
Upper-airway cough syndrome
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Skin and subcutaneous tissue disorders
Dandruff
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Skin and subcutaneous tissue disorders
Dermal cyst
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Skin and subcutaneous tissue disorders
Nail disorder
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Skin and subcutaneous tissue disorders
Photosensitivity reaction
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
7.7%
2/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Skin and subcutaneous tissue disorders
Sensitive skin
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Skin and subcutaneous tissue disorders
Skin induration
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Vascular disorders
Aneurysm
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Vascular disorders
Embolism
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Vascular disorders
Flushing
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.3%
1/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Vascular disorders
Hot flush
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.7%
2/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.4%
1/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Vascular disorders
Hypertension
|
11.1%
1/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
4.2%
1/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
12.5%
1/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
14.3%
1/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
20.0%
1/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Vascular disorders
Hypotension
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.3%
2/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
8.7%
2/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
5.3%
1/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
33.3%
1/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
|
Vascular disorders
Orthostatic hypotension
|
0.00%
0/9 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/24 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/23 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/8 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/7 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/19 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/5 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/3 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
3.8%
1/26 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
0.00%
0/29 • Start of treatment to 30 days post lase dose, up to 34.7 months for Serious adverse events; Start of treatment to 30 days post last dose, up to 23.7 months for other adverse events
|
Additional Information
Repare Therapeutics Medical Monitor
Repare Therapeutics Inc
Phone: 1 (857) 340-5402
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place